Унифлювек (универсальная гриппозная векторная вакцина)
Рандомизированное, двойное слепое, плацебо-контролируемое исследование 1 фазы универсальной гриппозной векторной вакцины Унифлювек двух уровней доз при двукратном интраназальном применении у здоровых добровольцев в возрасте от 18 до 49 лет
Постоянная ссылка: https://clinomir.ru/trials/permit/ru/628/2018-12-14/
Источник: ГРЛС — Государственный реестр лекарственных средств Минздрава России; ClinicalTrials.gov (U.S. National Library of Medicine); clinmarket. Что откуда
Простыми словами
Словарь терминов- Фаза I — первое применение у людей. Проверяют безопасность и подбирают дозу, участников немного.
- В исследовании участвуют здоровые добровольцы.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–49 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 120 чел. в стране «Россия».
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановая дата окончания (03.2020) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 7 · невключение: 23
Критерии включения
- Availability of signed informed consent.
- Adult men and women at the age from 18 through 49 years old.
- Diagnosis "healthy", verified by standard examination.
- Body weight ≥ 50 kg.
- The subjects, who are antibody-negative to influenza A/H1N1pdm virus (antibody titers ≤1:10 based on Hemagglutination inhibition assay (HIA)).
- Ability and voluntary desire to keep records in the Self-Observation Diary, as well as to attend all the visits of the study for the medical control.
- Consent of study subjects to use reliable contraception methods during the entire period of their participation in the study, as well as within 3 months after completion of participation in the study.
Критерии невключения
- Participation in another clinical study within three months prior to the beginning of this study; plans to participate in another study during the period of this study.
- Immunization with any other vaccine, not provided by the study within 6 months prior to inclusion in this study, or refusal to postpone another immunization until the end of the four-week period after completion of this study.
- Regular administration of irrigation therapy of the nasal cavity within the last six months prior to inclusion in this study or occasional application of this treatment method within two weeks prior to inclusion in this study.
- Frequent nosebleeds within the year before the study in the past medical history (> 5).
- Clinically significant anatomical pathology of the paranasal area or signs of surgical intervention in the area of the nose, sinus sinuses or traumatic injuries of the nose during the month before the beginning of screening.
- Symptoms of acute respiratory disease, including fever, or other acute diseases as of the screening date or within two weeks before the beginning of screening.
- Treatment with immunoglobulins or other blood products within three months prior to the beginning of screening or planning such treatment during participation in this study; blood/plasma donation (from 450 ml blood or plasma) in less than 2 months prior to screening.
- The presence or suspicion of various immunosuppressive or immunodeficient conditions or continuous administration (the drug is prescribed for more than 14 days of continous administration) of immunosuppressive drugs, immunomodulators during 6 months before inclusion in this study (for corticosteroids - greater than or equal to 0.5 mg/kg of prednisolone or other equivalent corticosteroids per day; topical and inhaled steroids, except for administration in the nasal cavity, are allowed).
- Participation in any previous studies to assess vaccines containing influenza viruses A/H1N1pdm09.
- Severe allergic reactions, including asthma, Quincke's edema, anaphylactic shock in the past medical history.
- Wheezing after a previous immunization with live influenza vaccine in the past medical history.
- Hypersensitivity after any previous vaccination against influenza and/or adverse effects caused by immunization, like body temperature above 40°C, fainting, non-febrile convulsions, anaphylaxis, when there is a minimal risk of association with the previous administration of any vaccine (not only against influenza).
- Suspected hypersensitivity to any components of the investigated vaccine, including chicken egg protein.
- Seasonal (spring or autumn) hypersensitivity to the natural factor effects.
- Acute or chronic clinically significant lesions in the lungs, the cardiovascular system, liver, endocrine, neurological and psychiatric diseases or renal dysfunction, as revealed based on the past medical history, physical examination or clinical laboratory findings, which may have an impact on the study results.
- Leukemia or any other malignant blood diseases or solid malignant neoplasms of other organs in the past medical history.
- Thrombocytopenic purpura blood-clotting disorders in the past medical history.
- Seizures in the past medical history.
- HIV, hepatitis B or C.
- Tuberculosis.
- Chronic alcohol addiction or chronic use of illegal drugs, drug abuse.
- Pregnancy or breastfeeding.
- Any condition that, according to the researcher, can increase the health risk for the volunteer participating in the study or influence the study results.
Источник: ClinicalTrials.gov, NCT04650971 · запись обновлена в реестре 3 декабря 2020.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 7
- Number of Adverse events — Day -7 (7 days before first dose) - Day 111
Цель исследования
A double-blind, randomized, placebo-controlled, Phase I clinical study of the safety, tolerability, reactogenicity and immunogenic activity of the universal influenza vector vaccine "UniFluVec" at two dose levels after two intranasal administrations in healthy adults. The volunteers randomized to the study group received intranasally 0.5 ml of the vaccine (0.25 ml in each nostril) as nasal aerosol stray twice with an interval of 3 weeks. The vaccine of the first dose level contained 6.7 log EID50/0.5 ml (50% egg infective dose) of attenuated recombinant influenza A/H1N1pdm09 virus; vaccine of the second dose level contained 7.7 log EID50/0.5 ml of attenuated recombinant influenza A/H1N1pdm09 virus.
The primary objective of the study was to evaluate the safety, tolerability and reactogenicity profile of vaccine "UniFluVec" based on the frequency and severity of adverse events. The secondary objective of the study was to assess the immunogenicity.
Области и заболевания
Где проходит
1 центр в 1 городеОткуда эта информация
-
ГРЛС — Государственный реестр лекарственных средств Минздрава России · № 628 от 14.12.2018 Официальный реестр · загружено 1 октября 2026Препарат, номер протокола, название, разрешение, фаза, сроки, число участников, спонсор, разработчик
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT04650971 Официальный реестр (США) · загружено 9 ноября 2026Цель, центры
-
clinmarket · № 1343 Каталог исследований · загружено 1 октября 2026Статус
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.